
Certara, Inc. — Investor Relations & Filings
Certara, Inc. is a company that accelerates drug discovery and development through the use of proprietary biosimulation software, technology, and expert services. It provides an end-to-end platform that supports clients across the entire drug development lifecycle, from discovery and preclinical research to clinical trials, regulatory submissions, and market access. The company's solutions leverage predictive simulation, data-driven modeling, and advanced analytics to help pharmaceutical and biotechnology organizations optimize trial design, justify dosing decisions, and navigate regulatory requirements. Key software products include Simcyp, Phoenix, and Pinnacle 21. Certara's offerings are designed to de-risk development, enhance efficiency, and increase the likelihood of bringing new medicines to patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Certara, Inc. (0001827090) (Filer) | 2026-04-22 | English | |
| ARS - Certara, Inc. (0001827090) (Filer) | 2026-04-03 | English | |
| DEF 14A - Certara, Inc. (0001827090) (Filer) | 2026-04-03 | English | |
| 4 - CERTARA, INC. (0001827090) (Filer) | 2026-03-02 | English | |
| 10-K - CERTARA, INC. (0001827090) (Filer) | 2026-02-26 | English | |
| 8-K - CERTARA, INC. (0001827090) (Filer) | 2026-02-26 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 35223149 | 8-K - Certara, Inc. (0001827090) (Filer) | 2026-04-22 | English | ||
| 33256151 | ARS - Certara, Inc. (0001827090) (Filer) | 2026-04-03 | English | ||
| 33255090 | DEF 14A - Certara, Inc. (0001827090) (Filer) | 2026-04-03 | English | ||
| 32899219 | 4 - CERTARA, INC. (0001827090) (Filer) | 2026-03-02 | English | ||
| 32899221 | 10-K - CERTARA, INC. (0001827090) (Filer) | 2026-02-26 | English | ||
| 32899220 | 8-K - CERTARA, INC. (0001827090) (Filer) | 2026-02-26 | English | ||
| 13319431 | Director's Dealing 2026 | 2026-01-12 | English | ||
|
2025
8 filings
| |||||
| 13319432 | FORM 8-K | 2025-12-11 | English | ||
| 13319433 | Major Shareholding Notification 2025 | 2025-11-25 | English | ||
| 13319434 | Major Shareholding Notification 2025 | 2025-11-13 | English | ||
| 13319435 | Director's Dealing 2025 | 2025-11-12 | English | ||
| 13319436 | 10-Q | 2025-11-06 | English | ||
| 13319437 | 8-K | 2025-11-06 | English | ||
| 13319438 | FORM 8-K | 2025-10-16 | English | ||
| 13319439 | Major Shareholding Notification 2025 | 2025-10-09 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
IMMUTEP LIMITED
Develops LAG-3 targeting immunotherapies for cancer and aut…
|
IMM | AU | Professional, scientific and te… |
|
IMMUTEP Ltd
Biotechnology company developing LAG-3 immunotherapies for …
|
IMMP | US | Professional, scientific and te… |
|
IMPACT BIOMEDICAL INC.
Develops biopharmaceutical products and technologies to pro…
|
IBO | US | Professional, scientific and te… |
|
IMUGENE LIMITED
Clinical-stage immuno-oncology company developing cancer im…
|
IMU | AU | Professional, scientific and te… |
|
IMV Inc.
Pioneering novel immunotherapies using the proprietary DPX®…
|
IMV | CA | Professional, scientific and te… |
|
INBIOGEN CO.,Ltd
A life sciences firm offering bioinformatics and data minin…
|
101140 | KR | Professional, scientific and te… |
|
Incannex Healthcare Inc.
A clinical-stage biopharma firm developing cannabinoid and …
|
IXHL | US | Professional, scientific and te… |
|
Indaptus Therapeutics, Inc.
Develops bacterial-based immunotherapies for cancer and vir…
|
INDP | US | Professional, scientific and te… |
|
InflaRx N.V.
Clinical-stage biopharmaceutical firm developing C5a/C5aR p…
|
IFRX | NL | Professional, scientific and te… |
|
Inhalation Sciences Sweden AB
Develops lab instruments and provides research for preclini…
|
ISAB | SE | Professional, scientific and te… |
Certara, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/31699/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=31699 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=31699 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=31699 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 31699}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Certara, Inc. (id: 31699)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.